Cost–Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China

Cost–Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China

PurposeTo evaluate the long-term cost-effectiveness of dapagliflozin, in addition to standard treatment, for the treatment of adult patients with type 2 diabetes (T2DM) at high cardiovascular risk from the Chinese healthcare system perspective.MethodsA decision-analytic Markov model with one-year cy...

Full description

Bibliographic Details
Main Authors: Kaiyu Huang, Yao Wang, Sijia Sun, Qian Zhu, Weifeng Zhou, Jiatao Liu, Dongchun Zhu, Xuefeng Xie
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Public Health
Subjects:
diabetes
cardiovascular disease
dapagliflozin
Markov model
cost-effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.936703/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.936703/full

Similar Items